Physician profile
Arvin Gupta
NPI 1841359353
$1,423.98
in general payments reported to CMS, 2019-2025
18 companies · $53.03 in 2025
The $53.03 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $268 · 2021: $136 · 2022: $136 · 2023: $190 · 2024: $231 · 2025: $53.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $186.39 | 2019-2024 | Lokelma |
| Boston Scientific Corporation | $142.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $112.07 | 2020-2023 | Acthar |
| Amgen INC. | $103.72 | 2019-2020 | |
| Horizon Therapeutics Plc | $96.93 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $95.87 | 2019-2024 | Ultomiris |
| Ani Pharmaceuticals, INC. | $94.29 | 2023-2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $93.99 | 2024-2025 | Tarpeyo |
| Vifor Pharma, INC. | $85.38 | 2019-2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $82.48 | 2020-2023 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $62.97 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $57.72 | 2019-2020 | |
| Travere Therapeutics, INC. | $54.98 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.98 | 2022-2023 | |
| Akebia Therapeutics INC | $42.16 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.92 | 2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $14.31 | 2025 | Lupkynis |
| Daiichi Sankyo INC. | $13.37 | 2024 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.